{"id":"W4293559767","doi":"10.1016/j.ygyno.2022.08.006","title":"Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma","year":2022,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"London Health Sciences Centre; University Health Network; Princess Margaret Cancer Centre","funders":"Universitat Autònoma de Barcelona; Universitat de Barcelona; Eisai; Regeneron Pharmaceuticals; Princess Margaret Cancer Foundation; AstraZeneca; National Cancer Institute; Novocure; U.S. Department of Defense","keywords":"Medicine; Gemcitabine; Placebo; Tolerability; Internal medicine; Adverse effect; Common Terminology Criteria for Adverse Events; Brief Pain Inventory; Surgery; Physical therapy; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019775,0.001339439,0.003416066,0.000379549,0.0004132343,0.0008826526,0.000762048,0.001663842,0.003973466],"category_scores_gemma":[0.002125091,0.0007153797,0.001891172,0.0004490707,0.000830083,0.0008639148,0.0003820435,0.002722812,0.0004396097],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004945606,"about_ca_system_score_gemma":0.0006238162,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005813327,"about_ca_topic_score_gemma":0.001422338,"domain_scores_codex":[0.9987589,0.0007888183,0.00009090661,0.0001908574,0.00008242797,0.00008811006],"domain_scores_gemma":[0.9985458,0.0005034935,0.0004511401,0.0001037546,0.00009725329,0.0002986114],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9761545,0.005652959,0.00204789,0.0005126564,0.001338343,0.00001700834,0.00004449716,0.0002933672,0.002286042,0.00003129545,0.0003061203,0.01131529],"study_design_scores_gemma":[0.8869738,0.1017098,0.008745075,0.0000269502,0.0008923451,0.00002659046,0.00002859462,0.0006569633,0.0005251059,0.000060501,0.0003315603,0.00002277289],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926811,0.003041325,0.0003938598,0.0002663817,0.0002852103,0.001708175,0.0005625033,0.0000557463,0.001005584],"genre_scores_gemma":[0.9946577,0.0009389083,0.0007370666,0.00040029,0.0002238274,0.001820369,0.0004827503,0.0000109664,0.0007280051],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003973466,"threshold_uncertainty_score":0.01329255,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0519709187733715,"score_gpt":0.3294032535004323,"score_spread":0.2774323347270607,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}